Researchers have demonstrated for the first time a potential route of the SARS-CoV-2 spike protein damaging the heart.
In study evaluating mice and human heart cells, the SARS-CoV-2 spike protein inflamed the heart muscle cells, which can lead to heart injury.
Embargoed until 8 a.m. CT/9 a.m. ET, Monday, July 25, 2022
(NewMediaWire) – July 25, 2022 – CHICAGO Heart damage is common among patients hospitalized with COVID-19, leading many to wonder how the virus affects the heart. Now, researchers have found that the spike protein from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus can lead to heart muscle injury through the inflammatory process, according to preliminary research to be presented at the American Heart Association’s Basic Cardiovascular Sciences Scientific Sessions 2022. The meeting, held in Chicago on July 25-28, offers the latest research on basic and translational cardiovascular science.
The spike protein is found on the surface of SARS-CoV-2, the virus that causes COVID-19. Spike proteins latch onto receptors known as angiotensin-converting enzyme 2 (ACE2) on target cells. The spike protein facilitates virus entry into healthy cells, which is the first step in infection. In addition to infecting the lungs, the virus can also spread to other organs leading to more damage to the body, severe infection and, among some people, death.
“It’s already known from the clinical side that COVID-19 infection can induce heart injury, however, what we don’t know is the mechanistic details of how this occurs. What we suspect is that the spike protein has unknown pathological roles,” said Zhiqiang Lin, Ph.D., lead author of the study and an assistant professor at the Masonic Medical Research Institute in Utica, New York. “Our data show that the spike protein from SARS-CoV-2 causes heart muscle damage. That’s why it’s important to get vaccinated and prevent this disease.”
“Host natural immunity is the first line of defense against pathogen invasion, and heart muscle cells have their own natural immune machinery. Activation of the body’s immune response is essential for fighting against virus infection; however, this may also impair heart muscle cell function and even lead to cell death and heart failure,” Lin said.
The researchers studied whether the SARS-CoV-2 spike protein activates the natural immune response in heart muscle cells. HCoV-NL63 is a coronavirus that infects the respiratory system without causing cardiac injury, although its spike protein also uses ACE2 to mediate virus entry. They studied the potential ability to cause heart disease of both SARS-CoV-2 spike protein and the NL63 spike protein. Their results showed that the SARS-CoV-2 spike protein activated the natural immune response in heart muscle cells and damaged the heart, but the NL63 spike protein did not.
“The fact that the SARS-CoV-2 spike protein is activating the natural immune response may explain the high virulence compared to the other coronaviruses,” Lin said. “The TLR4 signaling is the major pathway that activates the body’s natural immune response, and the SARS-CoV-2 spike protein activates TLR4, not the regular flu spike protein.”
To investigate the impact of the SARS-CoV-2 spike protein on the heart, researchers cloned the SARS-CoV-2 spike protein and the NL63 spike protein into the AAV9 viral vector. The AAV9 viral vector was delivered into lab mice to activate the spike protein in the heart muscle cells. They found that the AAV9-mediated the SARS-CoV-2 spike protein, and not the NL63 spike protein, caused heart dysfunction, hypertrophic remodeling (enlargement) and cardiac inflammation.
In lab testing of heart cells cultured in dishes, researchers also observed that the SARS-CoV-2 spike protein made heart muscle cells much larger compared to cells without either spike protein. “We found direct evidence that the SARS-CoV-2 spike protein is toxic to heart muscle cells,” Lin said.
During this study, researchers also examined a heart biopsy from a deceased patient with inflammation due to COVID-19. They detected the SARS-CoV-2 spike protein and TLR4 protein in both heart muscle cells and other cell types. In contrast, these two proteins were absent in a biopsy of a healthy human heart. “That means once the heart is infected with SARS-CoV-2, it will activate the TLR4 signaling,” Lin said. “Besides directly damaging the heart muscle cells, the spike protein itself is very inflammatory and may cause systemic inflammation that indirectly causes heart problems.”
ACE2 is an important enzyme controlling blood pressure. SARS-CoV-2 infection may impair ACE2 function, which in turn leads to blood pressure increase and, thereby, injures the heart. SARS-CoV-2 may also damage the heart through other unknown pathways.
“Our study provides two pieces of evidence that the SARS-CoV-2 spike protein does not need ACE2 to injure the heart. First, we found that the SARS-CoV-2 spike protein injured the heart of lab mice. Different from ACE2 in humans, ACE2 in mice does not interact with SARS-CoV-2 spike protein, therefore, SARS-CoV-2 spike protein did not injure the heart by directly disrupting ACE2 function. Second, although both the SARS-CoV-2 and NL63 coronaviruses use ACE2 as a receptor to infect cells, only the SARS-CoV-2 spike protein interacted with TLR4 and inflamed the heart muscle cells. Therefore, our study presents a novel, ACE2-independent pathological role of the SARS-CoV-2 spike protein, ” Lin said.
This research takes the first step toward determining whether the SARS-CoV-2 spike protein affects the heart. The researchers now plan to investigate how SARS-CoV-2 spike proteins cause inflammation in the heart. There are two potential ways: the first is that spike protein is expressed in the virus-infected heart muscle cells and thereby directly activates inflammation; the second is that the virus spike protein is shed into the bloodstream, and the circulating SARS-CoV-2 spike proteins damage the heart.
Co-authors are Caroline Sheldon, B.A.; Steven Negron, B.A.; Chase W. Kessinger, Ph.D.; Bing Xu, Ph.D.; William T. Pu, M.D.; and Chieh-Yu Lin, M.D., Ph.D. Authors’ disclosures are listed in the abstract. No funding was reported for this study.
Statements and conclusions of studies that are presented at the American Heart Association’s scientific meetings are solely those of the study authors and do not necessarily reflect the Association’s policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. Abstracts presented at the Association’s scientific meetings are not peer-reviewed, rather, they are curated by independent review panels and are considered based on the potential to add to the diversity of scientific issues and views discussed at the meeting. The findings are considered preliminary until published as a full manuscript in a peer-reviewed scientific journal. The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and biotech companies, device manufacturers and health insurance providers and the Association’s overall financial information are available here.
The American Heart Association’s Basic Cardiovascular Sciences Scientific Sessions (BCVS) is the world’s premier meeting dedicated to the latest advances in basic and translational cardiovascular science. The virtual meeting is being held at the Chicago Hilton, July 25-28, 2022. The primary goal of the meeting is to convene scientists from around the world with the common goal to discover pathways to cardiovascular therapeutics and promoting cardiovascular health. Sessions will focus on new therapies and insights in cardiovascular disease, as well as research in fields like microRNAs, cardiac gene and cell therapy, cardiac development, as well as tissue engineering and iPS cells. The American Heart Association’s Council on Basic Cardiovascular Sciences planned the BCVS 2022 Scientific Sessions program which will be of special interest to basic cardiovascular scientists, molecular/cellular biologists, physiologists, translational investigators, clinical trialists, practicing cardiologists, cardiovascular nurses and pharmacists. Follow the conference on Twitter at #BCVS22.
About the American Heart Association
The American Heart Association is a leading force for a world of longer, healthier lives. With nearly a century of lifesaving work, the Dallas-based association is dedicated to ensuring equitable health for all. We are a trustworthy source empowering people to improve their heart health, brain health and well-being. We collaborate with numerous organizations and millions of volunteers to fund innovative research, advocate for stronger public health policies, and share lifesaving resources and information. Connect with us on heart.org, Facebook, Twitter or by calling 1-800-AHA-USA1.
For Media Inquiries and AHA Expert Perspective:
AHA Communications & Media Relations in Dallas: 214-706-1173; email@example.com
Karen Astle: firstname.lastname@example.org, 214-706-1392
For Public Inquiries: 1-800-AHA-USA1 (242-8721)
heart.org and stroke.org